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Abstract
From chronic kidney disease (CKD) Stage 4 onwards, phosphate binders are needed in many pa-
tients to prevent the development of hyperphosphataemia, which can result in disturbed bone and
mineral metabolism, cardiovascular disease and secondary hyperparathyroidism. In this review, we
re-examine the use of magnesium-containing phosphate binders for patients with CKD, particularly
as their use circumvents problems such as calcium loading, aluminum toxicity and the high costs
associated with other agents of this class. The use of magnesium hydroxide in the 1980s has been
superseded by magnesium carbonate, as the hydroxide salt was associated with poor gastrointes-
tinal tolerability, whereas studies with magnesium carbonate show much better gastrointestinal
profiles. The use of combined magnesium- and calcium-based phosphate binder regimens allows a
reduction in the calcium load, and magnesium and calcium regimen comparisons show that mag-
nesium may be as effective a phosphate binder as calcium. A large well-designed trial has recently
shown that a drug combining calcium acetate and magnesium carbonate was non-inferior in terms
of lowering serum phosphate to sevelamer-HCl and had an equally good tolerability profile. Because
of the high cost of sevelamer and lanthanum carbonate, the use of magnesium carbonate could be
advantageous and drug acquisition cost savings would compensate for the cost of introducing
routine magnesium monitoring, if this is thought to be necessary and not performed anyway.
Moreover, given the potential cost savings, it may be time to re-investigate magnesium-containing
phosphate binders for CKD patients with further well-designed clinical research using vascular end
points.
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Introduction
Declining renal function is associated with increasing serum
phosphate levels, and while dietary restriction of phospho-
rus can help to control serum phosphate levels initially,
most patients will have hyperphosphataemia from chronic
kidney disease (CKD) Stages 3 or 4 onwards [1]. Phosphate
binders are therefore required, primarily to prevent and to
treat secondary hyperparathyroidism that results from hy-
perphosphataemia, but also because of increasing concern
that phosphate, and possibly calcium also, may have a
central role in vascular calcification in patients with CKD
[2]. The most recent guidelines [Kidney Disease: Improving
Global Outcomes (KDIGO)] suggest that individual values
of serum calcium and phosphate, evaluated together,
should be used to guide clinical practice rather than the
calcium 3 phosphate product which probably adds noth-
ing to clinical management of CKD patients [3]. Target
ranges for serum phosphate and calcium are shown in
Table 1 [3, 4], but it is important to note that so far, no
randomized controlled trial has tested the benefits or oth-
erwise of adhering to these targets—a situation that can-
not be allowed to continue as the costs of treatment
escalate. For this reason, the KDIGO guidelines suggest
that serum phosphate should simply be lowered towards
normal, pointing out that no prospective study has yet
examined specific target ranges in relation to outcomes.
Oral phosphate binders have been used for many years
to control phosphate levels in patients with CKD, but as yet
we have not found the ideal binder(s) in terms of improved
clinical outcomes, efficacy, patient adherence, safety and
cost. Traditional phosphate binders containing aluminum
or calcium have well-known drawbacks. While aluminum-
containing agents are highly efficient phosphate binders,
they are now prescribed less often in developed countries
because of proven toxicity with long-term use but remain
widely used in developing countries. Calcium-based salts
are inexpensive, effective and very widely used, but there
exists some concern about observational statistical associ-
ations between calcium load, hypercalcaemia and vascular
calcification [5]. Newer non-aluminum and non-calcium
agents, such as sevelamer hydrochloride/carbonate and
lanthanum carbonate have the dual advantage of avoiding
aluminum toxicity and decreasing the calcium burden, but
at high cost. Lanthanum carbonate’s potency also reduces
the high pill burden conferred by many binders including
sevelamer, although the introduction of sevelamer carbo-
nate granules is a welcome additional step towards im-
proving patient adherence.
In this review, we will re-examine the use of magnesium-
containing phosphate binders in patients with CKD. They
share the advantages of lanthanum and sevelamer in not
containing aluminum but are relatively inexpensive in
comparison (Table 2). However, many clinicians are not
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fully familiar with current understanding of magnesium
metabolism and usage in CKD. Therefore, there are various
perceptions and concerns that need to be re-examined
before nephrologists are likely to start using magnesium-
containing phosphate binders more widely. Most of these
concerns centre around hypermagnesaemia, the incidence
of gastrointestinal disorders and the necessity for monitor-
ing of serum magnesium. In this review, we will examine
how the use of magnesium-containing phosphate binders
developed from early studies with magnesium hydroxide as
an adjunct to aluminum hydroxide to the later use of mag-
nesium carbonate alone and as an adjunct to calcium car-
bonate or calcium acetate to reduce patients’ calcium load.
Studies of magnesium as a phosphate binder in dialysis
patients
Early studies: magnesium as a substitute for aluminum
hydroxide. The first studies to use magnesium compounds
as a phosphate binder in dialysis patients date from the
early 1980s as an attempt to reduce aluminum hydroxide
use (Table 3). This was understandable as some patients
found aluminum hydroxide to be unpalatable (so leading
to poor compliance), associated with constipation and occa-
sionally nausea and vomiting. More significantly, aluminum
is partially absorbed in the gut, accumulates in the body and
leads to aluminum toxicity [6, 7, 8]. The very early clinical
studies tended to use magnesium hydroxide, and these
trials were complicated by diarrhoeal symptoms or mild
hyperkalaemia associated with this salt of magnesium
[6, 9]. Although these studies also suffered from low num-
bers of patients, they nevertheless showed that magnesium-
containing phosphate binders could reduce the use of
aluminum [6, 9] and that parathyroid hormone (PTH) levels
were also reduced when they were used alone or in combi-
nation with aluminum [9].
The last study to use magnesium hydroxide as a phos-
phate binder was published in the late 1980s [8]. Although
haemodialysis patients participating in this study had the
gastrointestinal symptoms typical of other magnesium
hydroxide studies, it was notable for three main reasons.
Firstly, it was a long-term study, in which aluminum hy-
droxide was replaced by magnesium hydroxide (given in
addition to high doses of oral calcium) for 6 months in 20
patients and for 20 months in 12 patients. Secondly, in
addition to the control of serum phosphate, calcium, mag-
nesium and alkaline phosphatase, switching from alumi-
num to magnesium hydroxide lowered PTH (C terminal)
levels (from 260  214 pg/mL to 185  182 pg/mL) and
intake of elemental calcium [from 4.4 (110 mmol/day)
to 3.0 g/day (76 mmol/day)], non-significantly. Thirdly,
bone mineralization (mineral apposition rate) remained
constant throughout the study at approximately normal
levels (between 0.63 and 0.65 lm/day) as shown by bone
histomorphometry.
A final study that compared aluminum- and magnesium-
containing phosphate binders used magnesium carbonate
rather than magnesium hydroxide [7]. Although this was a
2-year study and involved a reasonable number of patients,
it was difficult to compare the two phosphate-binding regi-
mens: magnesium carbonate was used in hospital-based
chronic maintenance haemodialysis patients (n¼ 28), while
aluminum hydroxide was used in haemodialysis patients at
home (n ¼ 24). This study demonstrated that magnesium
carbonate was suitable for long-term use and was an ef-
fective phosphate binder when used with magnesium-free
dialysate. Some reduction in PTH was noted, although no
mention is made of the tolerability profiles of the two regi-
mens in this short paper. However, it was suggested that
magnesium carbonate has a better tolerability profile than
magnesium hydroxide, particularly with regard to gastro-
intestinal side effects, but there have been no direct com-
parisons of these regimens [10].
Later studies: magnesium- and calcium-containing
phosphate binders. Calcium carbonate and calcium
acetate started to be used as phosphate binders in the
1980s as an alternative to aluminum [11, 12]. Patients
undergoing continuous ambulatory peritoneal dialysis
participated in a 1-year, open-label parallel-group study
to compare a combination of magnesium carbonate plus
calcium carbonate (n ¼ 32) in equal proportions, with
calcium carbonate alone (n ¼ 10) or aluminum hydroxide
alone (n ¼ 8) [13]. A magnesium-free peritoneal dialysate
was used in the group given magnesium as a phosphate
binder. Serum phosphate levels were controlled equally
well with combined magnesium and calcium carbonate
Magnesium-containing phosphate binders have
certain intrinsic advantages: they do not contain
aluminum, and so their use avoids aluminum tox-
icity and allows calcium intake to be reduced or
eliminated; they have been in use for many years
and magnesium-containing phosphate binders
are relatively inexpensive compared with sevelamer-
or lanthanum-based binders.
Table 1. Calcium and phosphorus target and suggested ranges from K/DOQI and KDIGO guidelines [3, 4]
Analyte (disease stage) K/DOQI (2003) KDIGO (2009)
Serum phosphorus (CKD 3–5) 0.87–1.49 mmol/L (2.7–4.6 mg/dL) 0.81–1.45 mmol/L (2.5–4.5 mg/dL)
Serum phosphorus (CKD 5D)a 1.13–1.78 mmol/L (3.5–5.5 mg/dL) 0.81–1.45 mmol/L (2.5–4.5 mg/dL)
Serum calcium 2.10–2.37 mmol/L (8.4–9.5 mg/dL) 2.10–2.62 mmol/L (8.4–10.5 mg/dL)
Dialysate calcium 1.25 mmol/L (2.5 mEq/L) 1.25 or 1.50 mmol/L (2.5 or 3.0 mEq/L)
aCKD stage 5D, CKD stage 5 and patient is on dialysis (HD or PD).
Early studies comparing the use of aluminum hy-
droxide and magnesium hydroxide or magnesium
carbonate showed that magnesium could be used
as an effective phosphate binder, but it is widely
acknowledged that magnesium hydroxide caused
gastrointestinal side effects, whereas the carbo-
nate salt is much better tolerated.
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treatment as with calcium carbonate or aluminum hy-
droxide used alone. Mean (SD) phosphate levels after
1 year were 1.36 (0.41) mmol/L for combined treatment,
1.38 (0.27) mmol/L (calcium carbonate monotherapy) and
1.46 (0.5) mmol/L (aluminum hydroxide monotherapy).
There was, moreover, no significant difference (P > 0.05)
between groups in serum magnesium concentration or
PTH levels.
The use of combined magnesium carbonate/calcium
carbonate phosphate-binder treatment was compared
with calcium carbonate monotherapy in a 2-year, random-
ized, controlled crossover trial in 29 haemodialysis patients
[10]. The dialysate magnesium concentration was 0.25
mmol/L (0.6 mg/dL) in the magnesium carbonate plus cal-
cium carbonate group and 0.74 mmol/L (1.8 mg/dL) in the
calcium carbonate monotherapy group. Calcium carbonate
and magnesium carbonate doses were adjusted in both
groups to achieve target serum calcium concentrations
of 2.37–2.62 mmol/L (9.5–10.5 mg/dL) and serum phosphate
concentrations of<1.94 mmol/L (<6.0 mg/dL). Serum levels
of calcium, phosphate and magnesium were similar in the
combined and the monotherapy phases. However, the
control of phosphate levels in the combined magnesium
and calcium phase occurred despite the ingestion of sig-
nificantly less calcium binder. Mean elemental calcium
used (SD) was 2.9 (0.4) g/day during calcium carbonate
monotherapy and 1.2 (0.2) g/day during magnesium car-
bonate plus calcium carbonate treatment; P < 0.0001.
Moreover, the use of magnesium carbonate allowed higher
doses of intravenous calcitriol to be used without hyper-
calcaemia (0.8 lg/treatment with calcium carbonate
monotherapy to 1.5 lg/treatment with magnesium carbo-
nate plus calcium carbonate; P < 0.02). During this study,
the mean (SD) elemental magnesium intake was 465 
52 mg/day (range 214–858 mg/day), and despite this high
intake of magnesium, this was generally well tolerated: no
patients reported any gastrointestinal symptoms including
loose stools, diarrhoea or bloating. Serum magnesium levels
were slightly elevated but not different from the run-in levels.
Another study compared a combined phosphate-binder
regimen of magnesium carbonate plus a calcium salt to
monotherapy calcium carbonate [14]. In this 3-year parallel-
group study, 50 haemodialysis patients were randomized
to either combination therapy with calcium acetate [pills
containing 435 mg calcium acetate (110 mg elemental
calcium) plus 235 mg magnesium carbonate (60 mg ele-
mental magnesium)] or calcium carbonate monotherapy.
The dialysate was the same for both groups with calcium of
1.5 mmol/L and magnesium of 0.5 mmol/L. Dose adjustment
of both phosphate-binder groups was based on serum cal-
cium and phosphate concentrations and plasma intact
parathyroid hormone (iPTH) levels. Combination treatment
with magnesium carbonate and calcium acetate resulted
in significantly lower serum phosphate and calcium con-
centrations compared with calcium carbonate monother-
apy (both P< 0.05) (Figure 1), and a significant decrease in
plasma iPTH levels (P < 0.05). Indeed, iPTH levels rose
somewhat in the calcium monotherapy group. Combina-
tion therapy resulted in a significant increase in serum
magnesium concentration (P < 0.05), although this re-
mained within normal values (0.65–1.06 mmol/L). Safety
and tolerability of the regimens were not mentioned in this
publication [14].
A pilot study has compared combined magnesium carbo-
nate plus calcium carbonate with calcium acetate mono-
therapy [15]. Patients undergoing haemodialysis were
randomized in a 2:1 ratio to receive either calcium carbo-
nate plus magnesium carbonate (n ¼ 20; 86 mg elemental
magnesium, 100 mg elemental calcium) or calcium acetate
Table 2. Acquisition costs (in Euro) for phosphate binders in five European countriesa,b
Drug Dose Pack size Mean MSP DDD Mean cost per DDD
Sevelamer hydrochloride 800 mg 180 V145.59 D,Fr,UK,It,E 6.4 g V6.47 D,Fr,UK,It,E
Lanthanum carbonate 750 mg 90 V225.23 D,Fr,UK,It,E 2.25 g V7.51 D,Fr,UK,It,E
Calcium acetate/magnesium carbonate 435 mg 180 V25.91 D,UK,It,E 2.6 g V0.86 D,UK,It,E
Calcium acetate 667 mg 200 V15.57 UK,It,E 6.0 g V0.60 D,UK,It,E
950 mg 200 V9.17 D
Calcium carbonate 500–1750 mg 30–200 V2.64–V16.65 D,Fr,UK,It,E 10.0 g V1.15 D,Fr,UK,It,E
aDDD, defined daily dose; MSP, manufacturer selling price.
bD, Germany; Fr, France; UK, United Kingdom; It, Italy; E, Spain.
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Fig. 1. Significant decrease in serum calcium concentration in patients
given a phosphate binder consisting of calcium acetate plus magnesium
carbonate (versus calcium carbonate alone) [14]. (Reprinted from Deuber
[14], with permission from Dustri-Verlag, Dr. Karl Feistle GmbH & Co.).
Treatment with combined magnesium carbonate/
calcium carbonate phosphate binders was gener-
ally well tolerated: no patient reported gastrointes-
tinal symptoms.
Combination treatment with magnesium carbo-
nate and calcium acetate resulted in significantly
lower serum phosphate and calcium concentra-
tions compared with calcium carbonate monother-
apy (both P < 0.05).
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Table 3. Summary of clinical trials involving magnesium-containing phosphate binders in patients undergoing dialysisa
Year Author Journal Product Modality
Patients
(N) Design/duration Dialysate Result
1982 Guillot
et al. [6]
Nephron Mg(OH)2 and
Al(OH)3—separately and
in combination
HD 9 Four open study phases:
no phosphate binders
(period I: 2 weeks),
Mg(OH)2 alone
(II: 2–5 weeks),
Al(OH)3 plus Mg(OH)2
(III: 4–10 weeks), Al(OH)3
alone (IV: 4 weeks)
Mg, 0.5–0.75 mmol/L
(1.0–1.5 mEq/L) and
Ca, 1.5–1.6 mmol/L
(3.0–3.25 mEq/L)
Best control of serum P levels when
Al(OH)3 and Mg(OH)2 were used together.
1987 Oe
et al. [9]
Clin Nephrol Mg(OH)2 and
Al(OH)3—separately and
in combination
HD 18 Open, sequential: Al(OH)3
alone (period I: 6–9 months),
Mg(OH)2 alone
(II: 2–6.5 months)
then Al(OH)3 plus Mg(OH)2
(III: 4–13 months)
Period I: Mg, 0.75 mmol/L;
Periods II and III: Mg,
0.00 mmol/L
Allowed reduced aluminum usage. PTH
levels fell on Mg(OH)2 treatment (both
when used as monotherapy or in
conjunction with Al(OH)3).
1986 O’Donovan
et al. [7]
Lancet MgCO3 versus
Al(OH)3
HD 50 Two-year open-label study:
28 pts (chronic hospital-based
haemodialysis) given MgCO3,
22 pts (home-based dialysis)
given Al(OH)3
MgCO3 group: Mg < 0.2 mmol/L
and Ca, 1.65 mmol/L;
Al(OH)3 group: Mg, 0.85 mmol/L
and Ca, 1.65 mmol/L
MgCO3 suitable for long-term control
of serum phosphate levels when used alone,
but difficult to compare groups owing
to different dialysis regimens.
1988 Moriniere
et al. [8]
Nephrol Dial
Transplant
Mg(OH)2 versus
Al(OH)3
HD 20 Sequential open-label study:
20 pts for 6 months;
12 pts for 20 months.
Control period (with Al(OH)3): Mg,
0.75 mmol/L; during Mg(OH)2
period: Mg, 0.375 mmol/L
Replaced Al(OH)3 with Mg(OH)2 Diarrhoea
common.
Bone histomorphometry
performed
Reduced requirement for supplemental
calcium during Mg(OH)2 treatment. During
Mg(OH)2 treatment, serum PTH levels
declined non-significantly; stable serum
concentrations of P, Ca, Mg and alkaline
phosphatase.
1993 Parsons
et al. [13]
Nephron MgCO3/CaCO3
versus CaCO3
versus Al(OH)3
CAPD 50 One-year, open-label,
parallel-group study:
MgCO3 1 CaCO3
(Group I: n ¼ 32);
CaCO3 alone (II: n ¼ 10),
Al(OH)3 alone (III: n ¼ 8)
All patients given
MgCO3 1 CaCO3 were
given Mg-free dialysate
(Ca, 1.65 mmol/L)
Serum P levels were controlled equally well
in the MgCO3 1 CaCO3 group as in the
other groups, without evidence of
increased Mg levels. No significant
between-group difference in PTH.
1996 Delmez
et al. [10]
Kidney Int MgCO3/CaCO3
versus CaCO3
HD 29 Two-year, randomized,
controlled, crossover trial:
MgCO3 1 CaCO3 (Phase I);
CaCO3 alone (Phase II)
MgCO3 1 CaCO3 group:
Mg, 0.25 mmol/L (0.6 mg/dL),
Ca, 1.25 mmol/L (5 mg/dL)
CaCO3 alone: Mg, 0.74 mmol/L
(1.8 mg/dL), Ca, 1.25 mmol/L
(5 mg/dL)
Serum levels of Ca, P and Mg stable in both
phases. Use of MgCO3 enabled higher doses
of i.v. calcitriol without hypercalcaemia
(0.8 lg/treatment with CaCO3
monotherapy, to 1.5 lg/treatment with
MgCO3 1 CaCO3; P < 0.02) and reduced Ca
intake (from 2.9 to 1.2 g/day, respectively;
P < 0.0001).
2004 Deuber [14] Nieren- und
Hockdruck-
krankheiten
CaAc/MgCO3
versus CaCO3
HD 50 Three-year, randomized
parallel-group trial:
MgCO3 1 CaAc (Group I);
CaCO3 alone (Group II)
For both groups: Mg, 0.5 mmol/L
and Ca, 1.5 mmol/L
Serum levels of Ca and P and plasma iPTH
levels were lower in the MgCO3 1 CaAc
group (all P < 0.05 versus CaCO3 group).
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Table 3. Continued
Year Author Journal Product Modality
Patients
(N) Design/duration Dialysate Result
2007 Spiegel
et al. [15]
J Ren Nutr MgCO3/CaCO3
versus CaAc
HD 30 Twelve-week, randomized
open-label pilot study:
MgCO3 1 CaCO3 (Group I; n ¼ 20);
CaAc alone (Group II; n ¼ 10)
For both groups:
Mg, 0.375 mmol/L
(0.75 meq/L) and Ca,
1.25 mmol/L (2.5 meq/L)
Both regimens were generally well tolerated
and MgCO3/CaCO3 was at least as effective
in control of serum P as CaAc alone, but
required less elemental Ca ingestion.
2008 Tzanakis
et al. [16]
Int Urol
Nephrol
MgCO3
versus CaCO3
HD 46 Six-month, randomized
open-label study:
MgCO3 (Group I; n ¼ 25)
CaCO3 (Group II; n ¼ 21)
MgCO3 group: Mg, 0.3 mmol/L
and Ca, 1.50 mmol/L;
CaCO3 group:
Mg, 0.48 mmol/L and Ca,
1.50 mmol/L.
The Mg regimen showed equally effective
control of serum P and Mg, but better control
of serum Ca, than the Ca regimen. Good
tolerability profile for Mg regimen: 2 of 25
(8%) withdrew because of diarrhoea or high
Mg levels.
2009 Spiegel
et al. [17]
Hemodial Int MgCO3/CaCO3 HD 7 Eighteen-month open-label
pilot study to monitor CAC
and V-BMD
Composition of dialysate
not mentioned
There was no significant progression of the
CAC score and no significant change in
V-BMD, and thus Mg may have a favourable
effect on these parameters (though the size
of the study precludes any firm conclusions).
2009 McIntyre
et al. [19]
Clin J Am Soc
Nephrol
Fe–Mg
hydroxycarbonate
HD 63 Five-week, randomized,
placebo-controlled,
double-blind parallel-group
study: placebo
(Group I; n ¼ 21);
Fe–Mg hyroxycarbonate,
1 g tds (Group II; n ¼ 21);
Fe–Mg hyroxycarbonate,
2 g tds
(Group III; n ¼ 21)
Composition of dialysate
not mentioned
Lower dose had an acceptable tolerability
profile, but only about half of this group had
acceptable serum phosphorous control
(<1.78 mmol/L). Higher dose group had
acceptable phosphate control, with 81%
achieving levels < 1.78 mmol/L, but
tolerability profile was poor (13 of 21 [61.9%]
discontinued owing to adverse events).
Serum Mg levels were significantly elevated
in both Fe–Mg groups versus placebo.
2010 de Francisco
et al. [20]
Nephrol Dial
Transplant
CaAc/MgCO3
versus sevelamer-HCl
HD/HDF 255 Twenty-four-week,
randomized, controlled,
parallel-group
investigator-blinded
multicentre
study: CaAc/MgCO3
(Group I; n ¼ 126);
sevelamer-HCl
(Group II; n ¼ 129)
For both groups: Mg,
0.5 mmol/L and Ca,
1.5 or 1.25 mmol/L
(dependent on prior
prescription)
CaAc/MgCO3 was non-inferior to sevelamer,
with both treatments significantly lowering
serum P by 25 weeks of therapy. Both
treatments were equally well tolerated, with
minimal increases in serum Ca and
Mg levels in the CaAc/MgCO3 group.
aAl(OH)3, aluminium hydroxide; Ca, calcium; CaAc, calcium acetate; CAC, coronary artery calcification; CaCO3, calcium carbonate; CAPD, continuous ambulatory peritoneal dialysis; HD, hemodialysis; HDF, hemodiafil-
tration; i.v., intravenous; Mg, Magnesium; Mg(OH)2, magnesium hydroxide; MgCO3, magnesium carbonate; P, phosphate; pts, patients; tds, three-times daily; V-BMD, vertebral bone mineral density.
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alone (n ¼ 10) at their previous dose, or equivalent, of ele-
mental calcium, for 12 weeks. Phosphate-binder doses were
titrated to a target serum phosphate concentration of
under 5.5 mg/dL (1.78 mmol/L), and the dialysate was the
same for both groups, including calcium at 1.25 mmol/L
(2.5 meq/L) and magnesium at 0.375 mmol/L (0.75 meq/L).
Combination therapy with magnesium carbonate and cal-
cium carbonate offered control of serum phosphate that
was at least as good as that with calcium acetate alone. The
proportion of patients with serum phosphate <5.5 mg/dL
(the K/DOQI guideline threshold) was 70.6 and 62.5%, re-
spectively, in the efficacy phase (last 8 weeks) of the study
(P > 0.05). Moreover, this equivalent control was obtained
with a significant decrease in mean (SD) elemental calcium
consumption in the magnesium/calcium carbonate group
(908  24 mg/day versus 1743  37 mg/day, respectively;
P < 0.0001). Serum calcium concentrations were also
significantly higher in the calcium acetate monotherapy
group than in those taking magnesium carbonate plus cal-
cium carbonate (Figure 2; P < 0.003). Serum magnesium
levels were higher in patients receiving magnesium carbo-
nate than in the calcium acetate group (P < 0.03), but no
patients experienced symptoms related to hypermagne-
saemia [the highest serum magnesium reading was 1.95
mmol/L (3.9 meq/L)]. The pill burden per meal was signifi-
cantly, but not dramatically, lower in patients receiving
magnesium carbonate plus calcium acetate versus those
receiving calcium acetate alone (3.0  0.1 versus 3.4  0.1
pill per meal, P < 0.0001). In this study, safety and toler-
ability were investigated, and there were no significant
between-group differences, with both regimens being
generally well tolerated with a similar incidence of gas-
trointestinal symptoms.
A 6-month, randomized open-label study involving 46
haemodialysis patients investigated whether magnesium
carbonate was as effective as calcium carbonate (both
agents were the sole phosphate binder used in each group)
[16]. This study used lower magnesium concentrations
(0.3 mmol/L) in the dialysate for the magnesium group
compared with 0.48 mmol/L in the calcium group to re-
duce the risk of hypermagnesaemia, whereas dialysate
calcium was 1.50 mmol/L for both groups. There were no
significant differences in mean values for Months 1–6 be-
tween the magnesium and calcium groups for the control
of serum phosphate [1.77 mmol/L (5.47 mg/dL) versus 1.71
mmol/L (5.29 mg/dL), respectively; P ¼ NS] or magnesium
[1.06 mmol/L (2.57 mg/dL) versus 0.99 mmol/L (2.41 mg/
dL), respectively; P > 0.05], but serum calcium concentra-
tion was lower in the magnesium than in the calcium
group [2.28 mmol/L (9.13 mg/dL) versus 2.4 mmol/L
(9.60 mg/dL), respectively; P < 0.001]. Levels of iPTH were
not significantly different between the magnesium and cal-
cium groups after 6 months (251 versus 212 pg/mL, respec-
tively; P > 0.05). At Month 6, the percentages of patients
with serum levels of phosphate, Ca 3 P product and iPTH
that fell within the K/DOQI guidelines were similar in both
groups, whereas more patients in the magnesium group
(17/23; 73.91%) than in the calcium group (5/20, 25%)
had serum calcium levels that fell within these guidelines
(P < 0.01). Furthermore, magnesium carbonate was gener-
ally well tolerated with only 2 of 25 patients (8%) withdrawn
owing to adverse events (one because of diarrhoea, the
other because of recurrent hypermagnesaemia).
A very small, 18-month open-label pilot study of magne-
sium carbonate/calcium carbonate (elemental magnesium,
86 mg/elemental calcium, 100 mg) in haemodialysis
patients (n ¼ 7) is worth noting, as coronary artery calcifi-
cation (CAC) and vertebral bone mineral density (V-BMD)
were monitored [17]. Overall, there was no significant
progression of the CAC score and no significant change
in V-BMD, raising the possibility that magnesium may have
a favourable effect on these parameters (though the size
of the study precludes any firm conclusions). This study is
discussed further in this supplement, in the review con-
cerning magnesium, vascular calcification and outcomes
in patients with CKD [18].
Another study that examined magnesium levels in dialy-
sis patients in 2009 investigated the use of iron–magnesium
hydroxycarbonate (Fermagate) as a novel oral phosphate
binder [19]. Although this had a robust clinical study design
(5-week, randomized, placebo-controlled, parallel-group
three-arm trial testing two doses of phosphate binder)
and a reasonable number of haemodialysis patients
(n ¼ 63), the results stand alone from the rest of the mag-
nesium phosphate-binding literature. Iron–magnesium
hydroxycarbonate has a more complex structure and
different phosphate-binding characteristics than ‘plain’
magnesium-containing phosphate binders such as mag-
nesium carbonate. It contains magnesium and ferric iron
contained in an insoluble hydrotalcite structure with the
iron and magnesium held in tight crystalline layers, with
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Fig. 2. Lower serum calcium levels in patients given a magnesium-containing
phosphate binder (magnesium carbonate plus calcium carbonate) than in
those taking calcium acetate alone (P ¼ 0.003) Reprinted from Spiegel
et al. [15], Copyright 2007, with permission from Elsevier.
Combination therapy with magnesium carbonate
and calcium carbonate offered control of serum
phosphate that was at least as good as that with
calcium acetate alone, but with significantly de-
creased elemental calcium consumption.
Treatment with magnesium carbonate in compari-
son to calcium carbonate resulted in a similar pro-
portion of patients whose serum levels of phosphate,
Ca 3 P product and iPTH fell within the K/DOQI
guidelines, but more patients in the magnesium
group than in the calcium group had serum calcium
levels that fell within these guidelines (P < 0.01).
Moreover, magnesium carbonate was generally well
tolerated.
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carbonate groups which are exchanged for phosphate, lying
between the layers. In this short-term study, the proportion
of patients achieving serum phosphate levels below the
upper K/DOQI recommended value (1.78 mmol/L) in the
placebo, 1 and 2 g iron–magnesium hydroxycarbonate
groups was 30.0, 52.4 and 81.0%, respectively. Both treat-
ment groups had significantly increased serum magne-
sium levels compared with the placebo arm, with the
higher dose group suffering a greater number of adverse
events such as diarrhoea, vomiting and dyspepsia. The
most frequent reason for withdrawal during the treatment
and follow-up periods was an adverse event, accounting
for 20 (31.8%) patients (placebo, n ¼ 6; 1 g arm, n ¼ 1; 2 g
arm, n ¼ 13).
A large well-designed clinical trial published in 2010 com-
pared the combination product calcium acetate and mag-
nesium carbonate with sevelamer [20]. In this randomized,
controlled, parallel-group, investigator-blinded multicentre
study, 255 haemodialysis or haemodiafiltration patients
were randomized to receive calcium acetate/magnesium
carbonate (n ¼ 126) or sevelamer (n ¼ 129). The primary
efficacy measure was to show non-inferiority of calcium
acetate/magnesium carbonate to sevelamer in lowering se-
rum phosphate levels to below K/DOQI targets after 24
weeks of treatment. This was fulfilled, and there was no
significant difference between groups regarding the lower-
ing of serum phosphate levels at the end of the study (P ¼
0.069) (Figure 3). However, the area under the curve for
serum phosphate (P ¼ 0.0042) and the number of visits
above K/DOQI (1.78 mmol/L, P ¼ 0.0198) and KDIGO tar-
gets (1.45 mmol/L, P ¼ 0.0067) were significantly lower
with calcium acetate/magnesium carbonate. Also, the time
to reach serum phosphate levels of1.78 and1.45 mmol/
L when compared for the calcium acetate/magnesium car-
bonate and sevelamer regimens was significantly shorter
(i.e. 16 versus 30 days, P ¼ 0.0018 and 57 versus 140 days,
P ¼ 0.0052), using an identical dose titration protocol. Aver-
age (SD) daily study medication intake was also signifi-
cantly lower in the calcium acetate/magnesium carbonate
group by Week 25 than in the sevelamer group (7.3  3.03
versus 8.1  2.87 tablets/day, respectively; P ¼ 0.0420).
While ionized serum calcium levels were not significantly
different between groups, total serum calcium increased
slightly in the calcium acetate/magnesium carbonate group
(Figure 4: treatment difference 0.0477 mmol/L; P ¼ 0.0032)
but this was not associated with a higher risk of hypercal-
caemia. A small and asymptomatic increase in serum mag-
nesium also occurred in this group (treatment difference
0.2597 mmol/L, P < 0.0001). The tolerability profiles were
not affected as both groups had a similar number of ad-
verse events and both regimens were equally well tolerated.
There was, moreover, no significant difference between
groups with regard to the Gastrointestinal Quality of Life
Index. Overall, the authors concluded that calcium ace-
tate/magnesium carbonate had a good tolerability profile
and was at least as efficient in lowering serum phosphate
as sevelamer and so may represent an effective treatment
for hyperphosphataemia.
Benefits and concerns associated with use of magnesium
in CKD
Current usage of magnesium as a phosphate binder is not
as high as might be expected, and the reasons behind this
are difficult to discern. Partly it is due to the previous ab-
sence of major backing and promotion from a pharmaceut-
ical company, and perhaps concerns remain about the
gastrointestinal effects of the early hydroxide compounds
as opposed to the more recent carbonate. As a result of
both these factors, the CKD magnesium literature has
been relatively sparse up to this time. However, further
research is clearly required since magnesium usage has
the potential to minimize vascular calcification in dialysis
patients as first suggested by Meema in 1987 [21] (see the
review in this supplement by Massy and Dru¨eke [18]).
Concern about the potential for adverse events resulting
from hypermagnesaemia is genuine, but the few reports
that exist in the literature mostly relate to magnesium
levels of up to three times the upper limit of normal (which
are not reached in any of the studies looking at magnesium
as a phosphate binder) or the use of intravenous magne-
sium infusions such as in pre-eclampsia. The reduction in
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Fig. 3. Reductions in serum phosphate levels with treatment with either a
magnesium-containing phosphate binder (calcium acetate plus magne-
sium carbonate) or sevelamer hydrochloride [20]. Reprinted from de Fran-
cisco et al. [20], by permission of Oxford University Press.
When used as a phosphate binder, the combina-
tion of calcium acetate/magnesium carbonate
had a good tolerability profile and was non-inferior
to sevelamer-HCl.
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Fig. 4. Total serum calcium levels in patients given a magnesium-contain-
ing phosphate binder (calcium acetate plus magnesium carbonate) or sev-
elamer hydrochloride [20]. Reprinted from de Francisco et al. [20], by
permission of Oxford University Press.
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both HD and PD dialysate magnesium levels to 0.5–0.25
mmol/L in many countries greatly reduces the likelihood
of severe hypermagnesaemia in dialysis patients, and it is
often forgotten that prior to this reduction, many dialysis
patients were routinely moderately hypermagnesaemic
without apparent ill effects. However, a very practical con-
cern around greater use of magnesium as a phosphate
binder is that serum magnesium levels are not routinely
measured in many dialysis clinics. Some may argue that
routine monitoring is not necessary since the safety mar-
gin appears significant, but this is unlikely to satisfy the
concerns of nephrologists unfamiliar with usage of mag-
nesium-containing drugs. The cost of introducing magne-
sium monitoring would be offset by the lower cost of
magnesium-containing phosphate binders over sevelamer
or lanthanum, and most modern multi-channel biochem-
istry analysers can report magnesium if required without
major cost implications (note that magnesium measure-
ments are also covered by Jahnen-Dechent et al. [22] in
this supplement). In the UK, the approximate cost of per-
forming a serum magnesium test is £2–£3 (UK sterling); in
Germany, it is mostly the same price as serum calcium (e.g.
1.40 V, for private insurance 2.33 V).
Discussion
Over the last 20 years, magnesium-based phosphate bind-
ers have been tried as an alternative or supplement, first to
aluminum- and then to calcium-based phosphate binders.
In the first instance, this was to avoid aluminum toxicity
and secondly to avoid or minimize the risk of hypercalcae-
mia. The discussion of magnesium-containing phosphate
binder based on clinical trials in the literature is, however,
complicated for several reasons (Table 3). There are com-
paratively few published studies and of those that have
been published most are poor quality with either small
numbers of subjects or conducted over a short duration.
In addition, the older studies tended to use magnesium
hydroxide rather than magnesium carbonate, and it ap-
pears that magnesium hydroxide is associated with a high
degree of gastrointestinal adverse events. Newer formula-
tions using magnesium carbonate instead of magnesium
hydroxide appeared to result in an improved tolerability
profile [15, 16, 20]. The only side effects in these studies
were mild diarrhoea in few patients [15, 16]. Although
magnesium carbonate appears to be well tolerated, con-
cerns about gastrointestinal side effects still persist. With-
out doubt, the best quality trial to date is also the most
recent [20]. It is notable that there was no difference in
phosphate lowering and in tolerability using the combination
product magnesium carbonate/calcium acetate compared
to sevelamer-HCl and calculated costs for the treatment in
this trial were 80% lower for the combination product.
Given the high costs associated with sevelamer and lan-
thanum, the way ahead for magnesium-containing phos-
phate binders must include further clinical outcome trials
as well as pharmaco-economic evaluations. The designs of
such trials should be simple and of clinical utility, such as
randomization of new dialysis patients to either calcium
acetate or a non-calcium containing phosphate binder or
magnesium carbonate (alone or in combination with cal-
cium acetate) and should focus on vascular end points.
Moreover, as health care costs become an ever more im-
portant factor, re-examination of the use of magnesium as
a drug in CKD is timely.
Acknowledgements. The authors thank Dr Richard Clark and Dr
Martina Sintzel, for providing writing and editorial assistance on
behalf of Fresenius Medical Care Deutschland GmbH. Fresenius
also made an unrestricted educational grant to meet the cost of
preparing this article. These declarations are in line with the Euro-
pean Medical Writers’ Association guidelines.
Conflict of interest statement. M.W. has received speakers’ or con-
sultancy honoraria from and participated in clinical trials with
Abbott, Amgen, Fresenius and Ineos. A.J.H. has received speakers’
or consultancy honoraria from and participated in clinical trials
with Shire Pharmaceuticals, Ineos, Amgen Corp, Fresenius Inc.
and Mitsubishi Pharmaceuticals.
References
1. Rees L, Shroff RC. Phosphate binders in CKD: chalking out the
differences. Pediatr Nephrol 2010; 25: 385–394
2. Moe SM, Chen NX. Pathophysiology of vascular calcification in
chronic kidney disease. Circ Res 2004; 95: 560–567
3. Moe SM. KDIGO clinical practice guideline for the diagnosis,
evaluation, prevention, and treatment of Chronic Kidney Dis-
ease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl
2009; 76: S1–S130
4. National Kidney Foundation Inc. K/DOQI clinical practice
guidelines for bone metabolism and disease in chronic kidney
disease. Am J Kidney Dis 2003; 42: S1–S201
5. Hutchison AJ. Oral phosphate binders. Kidney Int 2009; 75:
906–914
6. Guillot AP, Hood VL, Runge CF et al. The use of magnesium-
containing phosphate binders in patients with end-stage renal
disease on maintenance hemodialysis. Nephron 1982; 30:
114–117
7. O’Donovan R, Baldwin D, Hammer M et al. Substitution of
aluminium salts by magnesium salts in control of dialysis
hyperphosphataemia. Lancet 1986; 1: 880–882
8. Moriniere P, Vinatier I, Westeel PF et al. Magnesium hydroxide
as a complementary aluminium-free phosphate binder to
moderate doses of oral calcium in uraemic patients on chronic
haemodialysis: lack of deleterious effect on bone mineralisation.
Nephrol Dial Transplant 1988; 3: 651–656
9. Oe PL, Lips P, van der MJ et al. Long-term use of magnesium
hydroxide as a phosphate binder in patients on hemodialysis.
Clin Nephrol 1987; 28: 180–185
10. Delmez JA, Kelber J, Norword KY et al. Magnesium carbonate
as a phosphorus binder: a prospective, controlled, crossover
study. Kidney Int 1996; 49: 163–167
11. Malberti F, Surian M, Poggio F et al. Efficacy and safety of long-
term treatment with calcium carbonate as a phosphate
binder. Am J Kidney Dis 1988; 12: 487–491
12. Mai ML, Emmett M, Sheikh MS et al. Calcium acetate, an effec-
tive phosphorus binder in patients with renal failure. Kidney
Int 1989; 36: 690–695
13. Parsons V, Baldwin D, Moniz C et al. Successful control of hyper-
parathyroidism in patients on continuous ambulatory peritoneal
dialysis using magnesium carbonate and calcium carbonate as
phosphate binders. Nephron 1993; 63: 379–383
14. Deuber HJ. Long-term Efficacy and safety of an oral phos-
phate binder containing both calcium acetate and magne-
sium carbonate in hemodialysis patients. Nieren- und
Hochdruckkrankheiten 2004; 33: 403–408
15. Spiegel DM, Farmer B, Smits G et al. Magnesium carbonate is
an effective phosphate binder for chronic hemodialysis pa-
tients: a pilot study. J Ren Nutr 2007; 17: 416–422
16. Tzanakis IP, Papadaki AN, Wei M et al. Magnesium carbonate
for phosphate control in patients on hemodialysis. A random-
ized controlled trial. Int Urol Nephrol 2008; 40: 193–201
17. Spiegel DM, Farmer B. Long-term effects of magnesium carbo-
nate on coronary artery calcification and bone mineral density
Use of magnesium in CKD i69
in hemodialysis patients: a pilot study. Hemodial Int 2009; 13:
453–459
18. Massy ZA, Dru¨eke TB. Magnesium and outcomes in patients
with chronic kidney disease: focus on vascular calcification,
atherosclerosis, and survival. Clin Kidney J 2012; 5 (Suppl 1):
i52–i61
19. McIntyre CW, Pai P, Warwick G et al. Iron-magnesium hydrox-
ycarbonate (fermagate): a novel non-calcium-containing
phosphate binder for the treatment of hyperphosphatemia
in chronic hemodialysis patients. Clin J Am Soc Nephrol
2009; 4: 401–409
20. de Francisco AL, Leidig M, Covic AC et al. Evaluation of cal-
cium acetate/magnesium carbonate as a phosphate binder
compared with sevelamer hydrochloride in haemodialysis
patients: a controlled randomized study (CALMAG study)
assessing efficacy and tolerability. Nephrol Dial Transplant
2010; 25: 3707–3717
21. Meema HE, Oreopoulos DG, Rapoport A. Serum magnesium
level and arterial calcification in end-stage renal disease. Kid-
ney Int 1987; 32: 388–394
22. Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin Kidney
J 2012; 5 (Suppl 1): i3–i14
i70 A.J. Hutchison and M. Wilkie
